On December 7, 2021 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported participation in the following conferences in December (Press release, Iovance Biotherapeutics, DEC 7, 2021, View Source [SID1234596545]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 7 at 1:40 p.m. ET
Live and archived webcast available at View Source
ESMO Immuno-Oncology Annual Meeting, December 8-11, 2021, Geneva, Switzerland
AKT inhibition during ex vivo TIL expansion enhances cytokine production and function while increasing the population of less differentiated (CD39-CD69-) CD8+ T-Cells
On-Demand Poster
The poster is available at View Source." target="_blank" title="View Source." rel="nofollow">View Source
American Society of Hematology Annual Meeting, December 11-14, Atlanta, Georgia
Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (IOV-CLL-01)
Poster Presentation: Monday, December 13 at 6:00 p.m. ET
The poster will be available at View Source at the start of the session.